Benitec Biopharma
BNTC
6 hedge funds and large institutions have $373K invested in Benitec Biopharma in 2018 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 0 closing their positions.
7,466% more capital inflows, than outflows
Capital inflows: $191K | Capital outflows: $2.53K
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
0.7% more ownership
Funds ownership: 0.78% → 1.48% (+0.7%)
0% more funds holding
Funds holding: 6 → 6 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$120K |
| 2 |
Morgan Stanley
New York
|
+$70.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$2.53K |
BNTC Hedge Fund Activity: Q1 2018 in Review
6 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Benitec Biopharma (BNTC) for Q1 2018, worth a combined $373K — up 96% from $190K a quarter earlier.
Fund positioning in BNTC was balanced in Q1 2018: 0 funds opened new positions, 0 closed out, 2 added to existing stakes and 1 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $120K. The largest seller was UBS Group, cutting an estimated $2.53K.
- 6 institutional investors held Benitec Biopharma (BNTC) as of Q1 2018, unchanged from Q4 2017.
- Funds reported $373K of Benitec Biopharma stock for Q1 2018, up 96% quarter-over-quarter.
- 0 funds opened new Benitec Biopharma positions in Q1 2018 and 0 closed out.
- The largest Benitec Biopharma buyer in Q1 2018 was Susquehanna International Group, an estimated $120K added.
- The largest Benitec Biopharma seller in Q1 2018 was UBS Group, an estimated $2.53K sold.
Based on aggregated 13F filings for Q1 2018.